🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Contribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis

Recruitingn/aAges 18 Years - anyAllNantes University Hospital
NCT05988437 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Hypersensitivity pneumonitis (HP) is a diffuse infiltrative pneumonitis (DIP) of immuno-allergic origin, caused by exposure to one or more antigenic substances of organic origin, in genetically predisposed individuals. It can take a fibrosing form, eventually leading to chronic respiratory failure. Diagnosis is based on a combination of clinical, biological, CT scan and histological evidence, and is made during multidisciplinary discussions (MDD) of diffuse interstitial lung disease. The antigens responsible, of domestic or professional origin, may be micro-organisms, animal proteins or chemical agents. However, the antigen remains unknown in almost 50% of cases. Lack of antigen identification is an independent risk factor for death in patients with fibrosing HP. In fibrosing forms, corticosteroid therapy does not appear to improve functional prognosis, and ninedanib, an antifibrosing t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient of legal age, * French-speaking patient, * Patient with a diagnosis of fibrosing PHS following a multidisciplinary discussion of diffuse interstitial lung disease hypersensitivity pneumonitis . * Patient who had received an information note presenting the study and who had not expressed opposition to participating in this research. Exclusion Criteria: * Opposition of the patient to participate in the study, * Patient under guardianship, curatorship or safeguard of justice, * Patients who have moved within the last 12 months, or who plan to move within the next 6 months, * Patients who have already had a visit from the indoor environment medical advisor.
💊

What it tests

  • Not listed
📍

Where

7 sites
CHU de Nantes
Nantes, France
CH Ancenis
Ancenis, France
CHU Angers
Angers, France
CH Chateaubriant
Châteaubriant, France
CHD LRSY
La Roche-sur-Yon, France
CH Cote de lumière
Les Sables-d'Olonne, France
CH St Nazaire
Saint-Nazaire, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy